

E 2
Contd

phenyl, biphenyl, naphthyl-C₁₋₈ alkyl, phenyl, biphenyl, naphthyl, phenyloxy, biphenyloxy, naphthyloxy, phenylamino, biphenylamino, naphthylamino, C₁₋₈ alkyl-carbonyl, phenylcarbonyl, biphenylcarbonyl, naphthylcarbonyl, phenylcarboxyl, biphenylcarboxyl, naphthylcarboxyl, phenylcarboxamide, biphenylcarboxamide, naphthylcarboxamide, halogen, CN, NRR', C₁₋₈ alkylamino;

n is an integer comprised between 1 and 4;

the symbol ----- means that the corresponding bonds a, b, c, d, e, f, g, h and i are single or double bonds, with the proviso that when b or f are a double bond, the group R₅ is absent; their pharmaceutically acceptable salts and esters.

REMARKS

The Examiner is thanked for the courtesy of extending a personal interview to the undersigned on May 21, 2003. The substance of the present Amendment was presented to the Examiner and the Examiner agreed that upon the filing of the present Amendment, the rejections of record would be reconsidered.

In the Office Action, the Examiner rejected the claims under 35 U.S.C. §112, first paragraph because the specification does not provide enablement for the compound of formula I when "aromatic heterocyclic" radicals are claimed. By this Amendment, the claims have been revised to delete heterocyclic radicals.

The Examiner also pointed to the breadth of the claims and the fact that two compounds were tested. No reference was cited in support of the Examiner's assertion that the application was not enabled with regard to R₁, R₂, R₃, R₄ and R₆. The Examiner is asked to consider that all of the test data of record points to the existence of activity in the claimed compounds and in the absence of evidence to the contrary, the applicant is not required to test each species that has been prepared. With regard to In re Wands, 8 USPQ2d 1400 (Fed. Cir. 1988), the Examiner is asked to consider that the Wands decision involved a situation where nine of 143 disclosed cell lines were made, 9 were tested

and 4 were found to have the high affinity and IgM serotype according to the Wands invention. This was held by the Wands court to be a disclosure that did not require undue experimentation and was therefore enabling. In the present case, the chemical compounds are related and no showing has been made that there is such unpredictability that one skilled in the art would expect that it would not be possible to practice the claimed invention without undue experimentation. For these reasons, it is requested that this ground of rejection be withdrawn.


In paragraph 2 of the Office Action, claims 3 and 27 were rejected under 35 U.S.C. § 112, second paragraph for failing to particularly point out and distinctly claim the subject matter that the applicant regards as the invention.

Reconsideration is requested.

Claims 3 and 27 were rejected because claim 3 did not specify "A" compound and claim 27 was dependent on a canceled claim. Both of these informalities have been corrected by this Amendment and withdrawal of this rejection is requested.


An early and favorable action is earnestly solicited.

Respectfully submitted,


James V. Costigan
Reg. No. 25,669


MAILING ADDRESS:

HEDMAN & COSTIGAN, P.C.
1185 Avenue of the Americas
New York, NY 10036-2601
(212) 302-8989

I hereby certify that this
correspondence is being
deposited with the United States Postal Service in
first class mail in an envelope addressed to
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22310-1450 7/14/62


Marked Up Copy of Amended Claims:

1. (twice amended) A fully and partially reduced benzo(c)quinolizine compound of formula (1):



wherein:

R_1 , R_2 , R_3 , R_4 and R_6 , which are the same or different, are chosen from the group consisting of: H, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, canphane, adamantane, phenyl, biphenyl, naphthyl, [saturated or aromatic heterocycle containing one to three N atoms, halogen, CN, azide, NRR' , C_{1-8} alkylamino, arylamino, C_{1-8} alkyloxy, aryloxy, COOR, CONRR', $C(=O)R$, wherein R and R', which are the same or different, are chosen from the group consisting of H, C_{1-8} alkyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, canphane, adamantane, phenyl, biphenyl, naphthyl, saturated or aromatic heterocycle containing one to three N atoms or naphthyl- C_{1-8}];

R_5 is chosen from the group consisting of: H, C_{1-8} alkyl, C_{1-8} alkyl-phenyl, biphenyl, naphthyl, COOR, CN[,] or phenyl, [saturated or aromatic heterocycle containing one to three N atoms, C_{1-8} alkyl-saturated or aromatic heterocycle containing one to three N atoms; C_{1-8} alkyl saturated or aromatic heterocycle containing one to three N atoms-ribose phosphate];

X is chosen from the group consisting of: O, $C(=O)R$, COOR, NO_2 , and CONNR', wherein R and R' are as above defined;

Q is chosen from the group consisting of single-bond, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, canphane, adamantane, CO, CONR, and NR, where R is as above defined;

W is chosen from the group consisting of H, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, canphane, adamantane, trifluoromethyl, C₁₋₈ alkoxy, C₁₋₈ alkoxy-C₁₋₈ alkyl, phenyl, biphenyl, naphthyl-C₁₋₈ alkyl, phenyl, biphenyl, naphthyl, phenyloxy, biphenyloxy, naphthyloxy, phenylamino, biphenylamino, naphthylamino, C₁₋₈ alkyl-carbonyl, phenylcarbonyl, biphenylcarbonyl, naphthylcarbonyl, phenylcarboxyl, biphenylcarboxyl, naphthylcarboxyl, phenylcarboxamide, biphenylcarboxamide, naphthylcarboxamide, halogen, CN, NRR', C₁₋₈ alkylamino, [saturated or aromatic heterocycle containing one to three N atoms wherein the groups alkyl, alkenyl, alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, canphane, adamantane, phenyl, biphenyl, naphthyl, saturated or aromatic heterocycle containing one to three N atoms, can be substituted];

n is an integer comprised between 1 and 4;

the symbol ----- means that the corresponding bonds a, b, c, d, e, f, g, h and i are single or double bonds, with the proviso that when b or f are a double bond, the group R₅ is absent; their pharmaceutically acceptable salts and esters.

2. (twice amended) A benzo(c)quinolizine compound of formula (1) according to Claim 1, wherein R₅ = H, C₁₋₈ alkyl-phenyl, biphenyl[,] or naphthyl [,] saturated or aromatic heterocycle containing one to three N atoms, C₁₋₈ alkyl-saturated or aromatic heterocycle containing one to three N atoms; or a C₁₋₈ alkyl-saturated or aromatic heterocycle containing one to three N atoms-ribose-phosphate];

X = O, COOH;

Q = single bond, CO, CONR, NR, wherein R

is chosen from the group consisting of H, C₁₋₈ alkyl,

cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, canphane, adamantane, phenyl, biphenyl, naphthyl [, saturated or aromatic heterocycle containing one to three N atoms, naphthyl-C₁₋₈alkyl];

W = H, F, Cl, Br, Me, t-butyl, C₁₋₈alkoxy, 2,5-dimethylhexyl, trifluoromethyl, 2,5-(di-trifluoromethyl)-phenyl, 4-methyloxy-phenyl, phenyl, phenyl-C₁₋₈alkyl, C₁₋₈alkylcarbonyl, phenylcarbonyl;

n = 1 and 2;

R₁, R₂, R₃, R₄ and R₆ = H, Me, CN, phenyl, COOR, CONRR', C(=O)R, wherein R and R' are the same or different and are chosen from the group consisting of H, C₁₋₈ alkyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, canphane, adamantane, phenyl, biphenyl[,] or naphthyl [, saturated or unsaturated heterocycle containing one to three N atoms, naphthyl-C₁₋₈].

3. (amended) A [B]benzo[c]quinolizine compounds according to Cl 1 of the formula:

2,3,4,4a,5,6,6a,7,8,9,10,10a-dodecahydro-(1H)-benzo[c]quinolizin-3-one;

8-chloro-2,3,4,4a,5,6,6a,7,8,9,10,10a-dodecahydro-(1H)-benzo[c]quinolizin-3-one;

2,3,4,4a,5,6,6a,7,8,9,10,10a-dodecahydro-8-methyl-(1H)-benzo[c]quinolizin-3-one;

2,3,4,4a,5,6,6a,7,8,9,10,10a-dodecahydro-4-methyl-(1H)-benzo[c]quinolizin-3-one;

2,3,4,4a,5,6,6a,7,8,9,10,10a-dodecahydro-1-methyl-(1H)-benzo[c]quinolizin-3-one;

2,3,4,4a,5,6,6a,7,8,9,10,10a-decahydro-(1H)-benzo[c]quinolizin-3-one;

8-chloro-2,3,4,4a,5,6,6a,7,8,9,10,10a-decahydro-(1H)-benzo[c]quinolizin-3-one;

2,3,4,4a,5,6,6a,7,8,9,10,10a-decahydro-8-methyl-(1H)-benzo[c]quinolizin-3-one;

2,3,5,6,6a,7,8,9,10,10a-decahydro-4-methyl-(1H)-benzo[c]quinolizin-3-one;

2,3,5,6,6a,7,8,9,10,10a-decahydro-1-methyl-(1H)-benzo[c]quinoliz-
 zin-3-one;
 (4a α ,6a β ,10a α)-3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aH)-
 benzo[c]quinoliz-3-one;
 [(4a α ,6a β ,10a α)-3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aH)-
 benzo[c]quinoliz-3-one;]
 3,4,5,6,6a,7,8,9,10,10a-decahydro-(1H)-benzo[c]quinoliz-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aH)-
 benzo[c]quinoliz-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-8-methyl-(4aH)-
 benzo[c]quinoliz-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-4-methyl-(4aH)-
 benzo[c]quinoliz-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-1-methyl-(4aH)-
 benzo[c]quinoliz-3-one;
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-4-methyl-(1H)-
 benzo[c]quinoliz-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-4,8-dimethyl-(1H)-
 benzo[c]quinoliz-3-one;
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-1-methyl-(1H)-
 benzo[c]quinoliz-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-1,4-dimethyl-(1H)-
 benzo[c]quinoliz-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-4-methyl-(4aH)-
 benzo[c]quinoliz-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-4,8-dimethyl-(4aH)-
 benzo[c]quinoliz-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-1-methyl-(4aH)-
 benzo[c]quinoliz-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-1,8-dimethyl-(4aH)-
 benzo[c]quinoliz-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-5-methyl-(1H)-
 benzo[c]quinoliz-3-one;
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-5-methyl-(1H)-
 benzo[c]quinoliz-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-5,8-dimethyl-(1H)-
 benzo[c]quinoliz-3-one;

2,3,5,6,6a,7,8,9,10,10a-decahydro-4,5-dimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-1,5-dimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-5-methyl-(4aH) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-5-methyl-(4aH) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-5,8-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-4,5-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-1,5-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-4,5-dimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-4,5,8-trimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-1,5-dimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-1,4,5-trimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-4,5-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-4,5,8-trimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-1,5-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-1,5,8-trimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-6-methyl-(1H) -
 benzo[c]quinolizin-3-one;
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-6-methyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-4,6-dimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-1,6-dimethyl-(1H) -


benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-6,8-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-6,8-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-4,6-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-1,6-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-4,6-dimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-4,6,8-trimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-1,6-dimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-1,4,6-trimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-4,6-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-4,6,8-trimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-1,6-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-1,6,8-trimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-5,6-dimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-5,6-dimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-4,5,6-trimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-1,5,6-trimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-5,6-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-5,6-dimethyl-(4aH) -
 benzo[c]quinolizin-3-one;

3,4,5,6,6a,7,8,9,10,10a-decahydro-5,6,8-trimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-4,5,6-trimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-1,5,6-trimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-1,5,6-trimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-4,5,6-trimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-4,5,6,8-tetramethyl-(1H) -
 benzo[c]quinolizin-3-one;
 8-chloro-2,3,5,6,6a,7,8,9,10,10a-decahydro-1,5,6-trimethyl-(1H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9,10,10a-decahydro-1,4,5,6-tetramethyl-(1H) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-4,5,6-trimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-4,5,6,8-tetramethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-1,5,6-trimethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-1,5,6,8-tetramethyl-(4aH) -
 benzo[c]quinolizin-3-one;
 5,6,6a,7,8,9,10,10a-octahydro-(3H) -benzo[c]quinolizin-3-one;
 8-chloro-5,6,6a,7,8,9,10,10a-octahydro-(3H) -benzo[c]quinolizin-3-
 one;
 5,6,6a,7,8,9,10,10a-octahydro-8-methyl-(3H) -benzo[c]quinolizin-3-
 one;
 5,6,6a,7,8,9,10,10a-octahydro-4-methyl-(3H) -benzo[c]quinolizin-3-
 one;
 8-chloro-5,6,6a,7,8,9,10,10a-octahydro-4-methyl-(3H) -
 benzo[c]quinolizin-3-one;
 5,6,6a,7,8,9,10,10a-octahydro-4,8-dimethyl-(3H) -
 benzo[c]quinolizin-3-one;
 2,3,5,6,7,8,9,10-octahydro-(1H) -benzo[c]quinolizin-3-one;
 8-chloro-2,3,5,6,7,8,9,10-octahydro-(1H) -benzo[c]quinolizin-3-

one;
 2,3,5,6,7,8,9,10-octahydro-8-methyl-(1H)-benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9-octahydro-(1H)-benzo[c]quinolizin-3-one;
 8-chloro-2,3,5,6,6a,7,8,9-octahydro-(1H)-benzo[c]quinolizin-3-one;
 2,3,5,6,6a,7,8,9-octahydro-8-methyl-(1H)-benzo[c]quinolizin-3-one;
 4a-benzyl-3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aH)-benzo[c]quinolizin-3-one;
 4a-benzyl-8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-(4aH)-benzo[c]quinolizin-3-one;
 4a-benzyl-3,4,5,6,6a,7,8,9,10,10a-decahydro-8-methyl-(4aH)-benzo[c]quinolizin-3-one;
 4a-benzyl-3,4,5,6,6a,7,8,9,10,10a-decahydro-4-methyl-(4aH)-benzo[c]quinolizin-3-one;
 4a-benzyl-3,4,5,6,6a,7,8,9,10,10a-decahydro-1-methyl-(4aH)-benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-4a-(4-pyridyl)methyl-(4aH)-benzo[c]quinolizin-3-one;
 8-chloro-3,4,5,6,6a,7,8,9,10,10a-decahydro-4a-(4-pyridyl)-methyl-(4aH)-benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-8-methyl-4a-(4-pyridyl)methyl-(4aH)-benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-4-methyl-4a-(4-pyridyl)methyl-(4aH)-benzo[c]quinolizin-3-one;
 3,4,5,6,6a,7,8,9,10,10a-decahydro-1-methyl-4a-(4-pyridyl)methyl-(4aH)-benzo[c]quinolizin-3-one[;]_

27. (amended) A method for the inhibition of 5 α reductase-I and/or 5 α reductase-II iso-enzymes as defined in claim [11] 13 where the pathology is selected from the group consisting of acne, baldness, prostatic cancer and prostatic hypertrophy in men and hirsutism in women.

28. (amended) A fully and partially reduced benzo(c)quinolizine compound of formula (1):




wherein:

R₅ is chosen from the group consisting of: H, C₁₋₈ alkyl, C₁₋₈alkyl-phenyl, biphenyl, naphthyl, COOR, CN[,] or phenyl[, saturated or aromatic heterocycle containing one N atom, C₁₋₈ alkyl-saturated or aromatic heterocycle containing one N atom; C₁₋₈ alkyl saturated or aromatic heterocycle containing one N atom-ribose phosphate];

Q is chosen from the group consisting of single-bond, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, camphane, adamantane, CO, CONR, and NR, where R is as above defined;

alkenyl, C₂₋₈ alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, camphane, adamantane, trifluoromethyl, C₁₋₈ alkoxy, C₁₋₈ alkoxy-C₁₋₈ alkyl, phenyl, biphenyl, naphthyl-C₁₋₈ alkyl, phenyl, biphenyl, naphthyl, phenyloxy, biphenyloxy, naphthyloxy, phenylamino, biphenylamino, naphthylamino, C₁₋₈ alkyl-carbonyl, phenylcarbonyl, biphenylcarbonyl, naphthylcarbonyl, phenylcarboxyl, biphenylcarboxyl, naphthylcarboxyl, phenylcarboxamide, biphenylcarboxamide, naphthylcarboxamide, halogen, CN, NRR' where R and R' are as above defined, C₁₋₈ alkylamino, [saturated or aromatic heterocycle containing one N atom wherein the groups alkyl, alkenyl, alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, camphane, adamantane, phenyl, biphenyl, naphthyl, saturated or aromatic heterocycle containing one N atom, can be substituted];
n is an integer comprised between 1 and 4;
the symbol ----- means that the corresponding bonds a, b, c, d, e, f, g, h and i are single or double bonds, with the proviso that when b or f are a double bond, the group R₅ is absent; their pharmaceutically acceptable salts and esters.

29. (new) A fully and partially reduced benzo(c)quinolizine compound of formula (1):



wherein:

R₁, R₂, R₃, R₄ and R₆, which are the same or different, are chosen from the group consisting of: H, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane,

cycloheptane, cyclooctane, norbornane, camphane, adamantane, phenyl, biphenyl[,] or naphthyl[,] saturated or unsaturated aromatic heterocycle containing one N atom, halogen, CN, azide, NRR', C₁₋₈ alkylamino, arylamino, C₁₋₈ alkyloxy, aryloxy, COOR, CONRR', C(=O)R, wherein R and R', which are the same or different, are chosen from the group consisting of H, C₁₋₈ alkyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, camphane, adamantane, phenyl, biphenyl, naphthyl, saturated or unsaturated heterocycle selected from the group consisting of pyridyl, imidazolyl, pyrrolyl, indolyl, triazolyl, pyrrolidinyl and piperidinyl, naphthyl-C₁₋₈];

R₅ is chosen from the group consisting of: H, C₁₋₈ alkyl, C₁₋₈alkyl-phenyl, biphenyl, naphthyl, COOR, CN, phenyl, [saturated or aromatic heterocycle selected from the group consisting of pyridyl, imidazolyl, pyrrolyl, indolyl, triazolyl, pyrrolidinyl and piperidinyl, C₁₋₈ alkyl-saturated or aromatic heterocycle selected from the group consisting of pyridyl, imidazolyl, pyrrolyl, indolyl, triazolyl, pyrrolidinyl and piperidinyl; C₁₋₈ alkyl saturated or aromatic heterocycle selected from the group consisting of pyridyl, imidazolyl, pyrrolyl, indolyl, triazolyl, pyrrolidinyl and piperidinyl-ribose phosphate];

X is chosen from the group consisting of: O, C(=O)R, COOR, NO₂, and CONNR', wherein R and R' are as above defined;

Q is chosen from the group consisting of single-bond, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, camphane, adamantane, CO, CONR, and NR, where R is as above defined;

W is chosen from the group consisting of H, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, camphane, adamantane, trifluoromethyl, C₁₋₈ alkoxy, C₁₋₈ alkoxy-C₁₋₈ alkyl, phenyl, biphenyl, naphthyl-C₁₋₈ alkyl, phenyl, biphenyl, naphthyl, phenyloxy, biphenyloxy, naphthyloxy, phenylamino, biphenylamino, naphthylamino, C₁₋₈ alkyl-carbonyl, phenylcarbonyl, biphenylcarbonyl, naphthylcarbonyl, phenylcarboxyl,

biphenylcarboxyl, naphthylcarboxyl, phenylcarboxyamide, biphenylcarboxyamide, naphthylcarboxyamide, halogen, CN, NRR', C₁₋₈ alkylamino, [saturated or aromatic heterocycle selected from the group consisting of pyridyl, imidazolyl, pyrrolyl, indolyl, triazolyl, pyrrolidinyl and piperidinyl wherein the groups alkyl, alkenyl, alkynyl, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, norbornane, camphane, adamantane, phenyl, biphenyl, naphthyl, saturated or aromatic heterocycle containing one N atom, can be substituted];

n is an integer comprised between 1 and 4;

the symbol ----- means that the corresponding bonds a, b, c, d, e, f, g, h and i are single or double bonds, with the proviso that when b or f are a double bond, the group R₅ is absent; their pharmaceutically acceptable salts and esters.